APA (7th ed.) Citation

T, M., JW, O., J, C., M, O., P, K., S, L., . . . JN, A. (2018). Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 24(7), 1617. https://doi.org/10.1158/1078-0432.CCR-17-2587

Chicago Style (17th ed.) Citation

T, Muliaditan, et al. "Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of Cancer." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 24, no. 7 (2018): 1617. https://doi.org/10.1158/1078-0432.CCR-17-2587.

MLA (9th ed.) Citation

T, Muliaditan, et al. "Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of Cancer." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 24, no. 7, 2018, p. 1617, https://doi.org/10.1158/1078-0432.CCR-17-2587.